Mode
Text Size
Log in / Sign up
N/A N=126 Randomized Single-blind Supportive Care

Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer

Cancer

Enrolled (actual)
126
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcome: Primary: Statement of Treatment Preferences (SOTP) a Tool to Measure Goals of Care. — 10; 22; 38; 19 Dyads — p=<0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
FAmily CEntered Advance Care Planning for Teens with Cancer (Behavioral)
Age
Pediatric, Adult, Older Adult · 14+ yrs
Sex
All
Sponsor
Maureen Lyon
Primary completion
Apr 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Statement of Treatment Preferences (SOTP) a Tool to Measure Goals of Care.
10; 22; 38; 19; 25; 1 <0.05 sig
SECONDARY
Patient-Reported Outcomes Measurement Information System (PROMIS Short Forms 8a - Pediatrics v. 2.0) is a Set of Person-centered Measures That Evaluates and Monitors Physical, Mental, and Social Health in Children and Adolescents.
13.0; 12.0; 10.0; 10.0; 16.0; 15.0 <0.05 sig
SECONDARY
Functional Assessment of Chronic Illness Therapy (FACIT)-Spirituality-12 Version 4 Expanded (FACIT-Sp-EX)
28.0; 26.0; 12.0; 14.0; 78; 75.0 <0.05 sig
SECONDARY
Family Appraisal of Caregiving Questionnaire for Palliative Care (FACQ-PC)
2.17; 2.34; 4.51; 4.61; 2.19; 2.44 <0.05 sig
SECONDARY
Advance Directive for Adolescent Only Located in the Electronic Health Record at Study Close Out.
60; 8; 15; 34

Summary

To test the efficacy of FACE-TC on key outcomes, the investigators propose using an intent-to-treat, longitudinal, prospective, multi-site, randomized controlled trial (RCT) design. Adolescents with cancer, aged 14 up to 20 years, and their families (N=130 dyads; N=260 participants) will be recruited and randomized to FACE-TC or Treatment as Usual (TAU) control. Participants will complete standardized questionnaires at baseline and 3, 6, 12, and 18 months post-intervention. Our goal is to assess the extent to which FACE-TC helps adolescents and young adults with cancer and their families: (1) reach and maintain better congruence in treatment preferences over time; (2) improve their quality of life; and (3) document goals of care and advance directives earlier in the course of their potentially life limiting illness.

Eligibility Criteria

AYA Inclusion Criteria:

  • Ever diagnosed with cancer;
  • Knows his or her cancer status;
  • Ages of 14 up to 20 years;
  • Ability to speak English;
  • Consent from the legal guardian for adolescents aged 14-17;
  • Consent from a surrogate for adolescents aged 18-20;
  • Assent from adolescent aged 14-17;
  • Consent from adolescent aged 18-20;

Inclusion Criteria for Legal Guardians of Adolescents Age 14-17:

  • Legal guardian of assenting adolescent participant;
  • Knows cancer status of adolescent;
  • Adolescent willingness to discuss problems related to cancer with them;
  • Age 18 or older;
  • Ability to speak English;
  • Consent to participate; Consent for his/her adolescent to participate;

Inclusion Criteria for Surrogates of AYAs Age 18-20:

  • Selected by adolescent aged 18 to 20;
  • Knows cancer status of adolescent;
  • Age 18 or older;
  • Ability to speak English;
  • Willingness to discuss problems related to cancer and EOL;
  • Consent to participate;

Exclusion Criteria - for AYA or surrogate decision-maker:

Developmental delay; foster care; active homicidality or suicidality, depression in the severe range

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02693665). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search